Mergers & Acquisitions Case Studies

We highlight a selection of M&A engagements that are representative of the Firm’s assignments.

View case studies >

Mergers & Acquisitions

Greenhill's M&A practice includes some of the most experienced professionals in the industry. Drawing on that experience, we are active across the full range of M&A advisory roles:

Sell-side Advisory

Leveraging our independence and lack of conflicts, we have a strong track record in sell side advisory roles. Acting for target companies, special board committees or selling shareholders, we can operate at the heart of any process, assist in negotiations and give impartial and objective advice about the merits of bids received.

Buy-side Advisory

We have a strong record of successful buy side advisory assignments in relation to public or private target companies and are able to advise interested buyers on attractive targets through our global network of relationships.

Merger Advisory

Greenhill is well qualified to assist clients on merger transactions given the long experience of its partners and professionals, an assurance of total discretion and a lack of conflicting interests. Greenhill has a number of sizeable mergers in its list of completed transactions both in the US and internationally.

Special Advisory

Various advisory work that we undertake does not fit a conventional ‘transaction’ definition. Examples include our work advising the Australian National Rugby League Commission on the sale of television broadcast rights and work for the global partnership of Arthur Andersen in the immediate aftermath of the cases that followed the collapse of Enron. We believe that Greenhill’s independence, experience, expertise and discretion positions us well for special advisory assignments.

Cross-border Advisory

Greenhill’s network of international offices and our ‘single Firm’ operating model allow us to offer clients a seamless cross-border advisory service with a truly global perspective.

Recent Transactions

20-Jun-16
$NA
israel.gif
Target: 

U.S. rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.

india.gif
Acquiror: 
Zydus Cadila

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights to 2 generic drug products to Zydus Cadila

17-Jun-16
$310 million
uk.gif
Target: 

Dobbies Garden Centres

uk.gif
Acquiror: 
Investor group led by Midlothian Capital Partners and Hattington Capital

Advised Tesco plc, a listed FTSE 100 retailer, on its sale of Dobbies Garden Centres to an investor group led by Midlothian Capital Partners and Hattington Capital

16-Jun-16
$40 million
israel.gif
Target: 

U.S. rights to 5 generic injectable drug products from Teva Pharmaceutical Industries Ltd.

U.S.A. flag
Acquiror: 
Sagent Pharmaceuticals, Inc.

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights to 5 generic injectable drug products  to Sagent Pharmaceuticals, Inc. 

15-Jun-16
$414 million
U.S.A. flag
Target: 

Aegerion Pharmaceuticals

canada.gif
Acquiror: 
QLT Inc.

Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization

11-Jun-16
$350 million
israel.gif
Target: 

U.S. rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.

india.gif
Acquiror: 
Dr. Reddy’s Laboratories

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights to 8 generic drug products to Dr. Reddy’s Laboratories

Pages

show all